Telehealth Weight Loss/GLP-1 Prescribing: What PMHNPs Can Do in North Carolina

If you’re a psychiatrist or psychiatric nurse practitioner, you’ve probably noticed: your patients aren’t just asking about depression or ADHD anymore. They’re asking about Ozempic, Wegovy, and weight loss. Many are on antipsychotics or mood stabilizers that caused 20, 30, 50+ pounds of weight gain. They’re struggling with metabolic syndrome. And they know GLP-1 medications work.

So the question comes up: Should I be prescribing weight-loss medications? More importantly: Can I legally prescribe them, and does it make sense for my practice?

The short answer: Yes, in most cases — but the details matter tremendously. State regulations, scope of practice rules, telehealth restrictions, and reimbursement all vary wildly. Some states welcome psychiatric providers prescribing weight-loss meds; others throw up roadblocks at every turn.

Let’s break down what you need to know.

Why Psychiatrists Are Entering the Weight Management Space

This isn’t about chasing trends. It’s about integrated care.

The psychiatric-metabolic connection is real. Many of your patients gained weight from the very medications you prescribed — atypical antipsychotics, lithium, mirtazapine, certain SSRIs. Obesity worsens depression, anxiety, and self-esteem. Metabolic syndrome increases dementia risk and overall mortality. You’re already monitoring lipids, glucose, and blood pressure for patients on psych meds.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) have shown benefits beyond weight loss in early research: reduced cravings in substance use disorders, potential mood stabilization, decreased inflammation affecting brain health. As Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, puts it: ‘If we truly understand that these systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’

You’re already treating the whole patient. Adding a medication that addresses medication-induced weight gain or co-morbid obesity isn’t scope creep — it’s comprehensive care.

That said, competency matters. Prescribing GLP-1s requires understanding metabolic physiology, contraindications (like pancreatitis history or medullary thyroid cancer risk), dosing titration, and side effect management. Many psychiatrists pursue additional training — obesity medicine CME, or even board certification through the American Board of Obesity Medicine (ABOM), which explicitly welcomes any physician specialty.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Safety Question: Do GLP-1s Cause Psychiatric Side Effects?

You’ve seen the headlines: ‘Ozempic linked to suicidal thoughts.’ Should you worry?

Current evidence is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. The FDA and European Medicines Agency reviewed the data and found no causal link. In fact, clinical trials like the STEP trials showed GLP-1-treated patients had slightly lower rates of depressive symptoms compared to controls.

Real-world data from millions of patients supports this. Psychiatrists like Dr. Lewis report using low-dose GLP-1s alongside therapy and lifestyle changes with ‘meaningful results and minimal side effects’ for patients struggling with both obesity and mental health issues.

The bottom line: With appropriate monitoring (especially in patients with active suicidal ideation or severe eating disorders), GLP-1s appear safe from a psychiatric standpoint. The bigger concern is often GI side effects — nausea, constipation — which are manageable with slow titration.

State-by-State Reality: Who Can Prescribe What

Here’s where it gets complicated. Your ability to prescribe weight-loss medications depends heavily on:

• Your credential (MD/DO vs. PMHNP)
• Your state’s scope-of-practice laws
• Specific state regulations on weight management
• Telehealth restrictions (if applicable)

Psychiatrists (MD/DO): Broad Authority with State-Specific Rules

As a physician, you have full prescriptive authority in all 50 states for FDA-approved weight-loss medications. You can prescribe:

• GLP-1 agonists (Wegovy, Saxenda, Zepbound/Mounjaro for obesity)
• Controlled appetite suppressants (phentermine, phendimetrazine)
• Other agents (orlistat, naltrexone-bupropion, topiramate combinations)

However, certain states impose clinical practice standards you must follow:

Florida requires:

• Patient must have BMI ≥30 (or ≥27 with comorbidity)
• Documented comprehensive exam (can be conducted by delegated APRN/PA)
• Written informed consent
• Quarterly follow-ups (at least every 3 months)
• Providing patients with Florida’s ‘Weight-Loss Consumer Bill of Rights’

Florida also prohibits prescribing controlled substances via telehealth for weight loss (only allowed for psychiatric disorders, addiction treatment, or inpatient care). So you can prescribe Wegovy (non-controlled GLP-1) via telemedicine to Florida patients, but not phentermine unless you conduct an in-person visit or the patient has a qualifying psychiatric diagnosis.

New Jersey requires:

• Comprehensive physical exam and lab work
• Assessment and treatment of any psychiatric conditions prior to or alongside weight-loss medication (an area where psychiatric providers excel)
• Documented nutritional counseling, exercise, and behavior modification plan
• Ongoing monitoring at each visit

Virginia mandates:

• Physical exam before prescribing
• Follow-up within 30 days of starting medication
• Monthly visits initially
• Documented diet and exercise program

Other states (Texas, California, New York, Pennsylvania, Illinois) don’t impose specific obesity-treatment protocols beyond standard medical practice, but best practice is to document BMI ≥30 or ≥27 with comorbidity (matching FDA indications), obtain informed consent, and schedule regular follow-ups.

PMHNPs: It Depends Where You Practice

Nurse practitioners face a patchwork of state laws:

Full Practice Authority States (~26 states + DC): PMHNPs can prescribe weight-loss medications independently after meeting experience requirements.

• New York: After 3,600 hours of collaborative practice, NPs can practice independently
• Illinois: After 4,000 hours of experience + 250 CE hours, APRNs can obtain Full Practice Authority (including controlled substance prescribing)
• California: Phasing in independence via AB 890 — experienced NPs can practice without standardized procedures in group settings (2023+), and ‘104 NPs’ can open independent practices starting January 2026. However, controlled substance prescribing for weight loss still requires physician oversight, and California’s Corporate Practice of Medicine doctrine means NP-owned weight-loss clinics need physician involvement in the business structure.

Restricted/Collaborative States: PMHNPs must have a formal agreement with a physician.

• Texas: All NPs require a Prescriptive Authority Agreement with a TX-licensed physician. The agreement must detail supervision, monthly quality meetings, and chart review. One physician can supervise up to 7 NPs/PAs in facility-based practice.
• Florida: APRNs need a written protocol with a supervising physician. Even Florida’s ‘Autonomous APRN’ registration (available only to primary care NPs with 3,000+ hours experience) excludes psychiatric NPs and doesn’t permit independent controlled substance prescribing.
• Pennsylvania: CRNPs need a Collaboration Agreement with a physician to prescribe. The physician must be listed on prescriptions alongside the NP.

Practical reality: Even in independent practice states, some insurers and pharmacies require physician involvement for high-cost GLP-1 prescriptions due to prior authorization complexity or internal policies — despite no legal requirement.

Scope of Practice Consideration for PMHNPs:You’re trained in psychiatric care, not endocrinology. Is prescribing weight-loss meds within your scope?

Answer: Scope is about competency, not title. If you:

• Gain additional training in obesity medicine (CME courses, certification programs)
• Are treating weight issues that intersect with mental health (medication-induced weight gain, binge eating, etc.)
• Work within a collaborative model or with physician oversight where required
• Document your rationale and clinical decision-making

…then yes, it’s defensible. Many PMHNPs successfully integrate weight management, especially for patients already under their psychiatric care. The key is not advertising yourself as a standalone weight-loss clinic without appropriate credentials — that invites regulatory scrutiny.

Telehealth Prescribing: Federal Permission, State Restrictions

Telehealth is ideal for weight management — convenient for patients, efficient for providers. But state laws create compliance traps.

Federal law (via DEA waivers extended through December 31, 2025) allows prescribing controlled substances via telehealth without an initial in-person exam. This includes phentermine (Schedule IV), the most common prescription appetite suppressant.

But states can override federal rules. And some do.

States that prohibit or severely restrict telehealth controlled-substance prescribing:

• Florida: Bans controlled substance prescribing via telehealth except for psychiatric treatment, inpatient care, or addiction treatment. Weight loss doesn’t qualify. You cannot prescribe phentermine via telemedicine to Florida patients unless there’s a documented psychiatric indication. Non-controlled GLP-1s (Wegovy, etc.) are fine via telehealth.
• Alabama: Requires an initial in-person exam before prescribing any controlled substance, effectively banning remote starts for phentermine.
• South Carolina, Idaho: Have similar in-person requirements for controlled substances.

States with no additional restrictions beyond federal law:

• Texas, California, New York, Pennsylvania, Illinois (as of 2026) allow telehealth controlled substance prescribing if federal rules are met and standard of care is followed.

For GLP-1 agonists (semaglutide, tirzepatide, liraglutide) — which are not controlled substances — telehealth prescribing is generally permitted in all states, provided you:

• Establish a valid patient-provider relationship (usually via video visit)
• Conduct an appropriate evaluation (history, review of vitals/labs, discussion of risks/benefits)
• Document everything thoroughly
• Follow any state-specific obesity treatment protocols (like Florida’s quarterly follow-up rule)

Best practices for telehealth weight management:

• Use video for initial consults (not just phone or questionnaire)
• Require patients to submit recent weight, blood pressure, and relevant labs
• Check your state’s Prescription Drug Monitoring Program (required in most states for controlled substances)
• Schedule regular follow-ups per state requirements (monthly in VA initially, every 3 months in FL)
• Partner with local labs or telehealth-integrated lab services for metabolic panels

Case in point: In 2023, a Mississippi physician had his license suspended for prescribing Ozempic through an instant-messaging platform with no audio/video evaluation. The board deemed it a failure to establish a proper patient relationship. Even if your state law doesn’t explicitly ban asynchronous prescribing, the standard of care for weight management likely requires visual assessment.

Reimbursement: Can You Actually Get Paid?

A few years ago, weight-loss medications were largely cash-pay. That’s changing fast.

Medication Coverage

Commercial insurance: Most major insurers now cover FDA-approved GLP-1 weight-loss medications (Wegovy, Saxenda, Zepbound) with prior authorization. Requirements typically include:

• BMI ≥30 or ≥27 with comorbidity (diabetes, hypertension, dyslipidemia)
• Documentation of lifestyle interventions (diet, exercise counseling)
• Sometimes proof of previous weight-loss attempts

Some plans impose quantity limits — BCBS Texas, for example, limits initial prescriptions to 30-day supplies to monitor adherence before approving refills.

Medicare: As of late 2025, Medicare announced it will begin covering anti-obesity medications like Wegovy and Mounjaro — a massive policy shift. This opens treatment to millions of seniors. Implementation details are rolling out through 2026.

Medicaid: Coverage varies by state. Some state Medicaid programs already cover GLP-1s for obesity; others are expanding coverage following Medicare’s lead.

Bottom line: Unlike 3-5 years ago, you can now get most patients’ weight-loss medications covered by insurance, assuming you meet prior auth criteria. This dramatically improves patient access and compliance.

Visit Reimbursement

For the consultation itself, you’ll typically bill:

• Evaluation & Management codes (99213-99215 for established patients, 99203-99205 for new patients)
• Psychiatric medication management codes (90863 if combined with therapy)
• Obesity counseling codes (G0447 for 15-minute behavioral counseling, though this is more commonly used by primary care)

Telehealth parity laws in many states ensure telehealth visits are reimbursed equally to in-person:

• California, New York, Illinois: Strong parity laws for commercial insurance
• Pennsylvania: Partial parity (mental health at parity, other services vary)
• Texas: Coverage parity (insurers must cover telehealth if they cover in-person) but payment parity still evolving
• Florida: No blanket parity law, but many plans reimburse telehealth equally

Medicare continues to reimburse telehealth mental health visits at office rates through at least 2025 (likely extended into 2026).

Psychiatrist vs. PMHNP reimbursement:

• Psychiatrists (MD/DO): Paid at 100% of physician fee schedule
• PMHNPs: Typically paid at 85% of physician fee schedule by Medicare; varies by commercial payer (some pay 90-100%)
• Exception: Illinois Medicaid reimburses APRNs at 100% of physician rates — a progressive policy to encourage NP utilization

Realistic revenue:

• Initial psychiatric eval with med management (90792): ~$200 (Medicare/most insurance)
• 15-20 minute follow-up med check (99213/99214): ~$75-120
• If you combine weight management with existing psychiatric care for the same patient, you’re adding value without necessarily adding visit time

Most telehealth platforms handle billing for you or pay you per consultation, abstracting away the insurance complexity.

The Economics: Platform vs. DIY Marketing

Let’s talk honestly about patient acquisition.

DIY marketing for a weight-loss practice is expensive and time-consuming:

• SEO: 6-12 months of consistent investment ($2,000-5,000/month for content, link building, technical optimization) before meaningful patient flow
• Google Ads: Mental health and weight-loss keywords cost $15-40+ per click. Most clicks don’t convert. Realistic cost per booked patient: $200-400+ when you factor in ad spend, testing, and no-shows
• Directory listings (Psychology Today, Zocdoc): Monthly fees ($30-300) + per-booking charges ($35-100+) + you’re competing with hundreds of other providers on the same page
• Hidden costs: Staff time to handle and qualify leads, failed campaigns, months of spend with no ROI

Total realistic DIY cost to acquire one qualified psychiatric patient through paid marketing: $200-500+ per patient when you add everything up.

For most providers — especially those starting out or scaling — that’s a gamble. You’re spending $3,000-5,000/month with uncertain results.

Platform model (like Klarity Health):

• No upfront marketing spend
• No monthly subscription fees
• Pay-per-appointment: You pay a standard listing fee only when a pre-qualified patient books with you
• Pre-matched patients: Already screened for insurance, specialty needs, availability
• Built-in telehealth infrastructure: No separate platform costs
• Both insurance and cash-pay patient flow
• You control your schedule: Only pay when you see patients

The math is simple: Instead of gambling $3,000-5,000/month on marketing channels that might not work, you pay only when a qualified patient shows up. That’s guaranteed ROI vs. throwing money at Google and hoping.

For weight-loss specifically: The patient demand is high (obesity affects 42% of U.S. adults), and with expanding insurance coverage for GLP-1s, more patients can afford treatment. A platform that handles patient acquisition lets you focus on clinical care, not marketing troubleshooting.

Practical Steps to Add Weight Management to Your Practice

1. Assess your competency

• Take obesity medicine CME courses (ABOM offers comprehensive training)
• Consider pursuing ABOM board certification if you plan to make this a significant part of your practice
• Review GLP-1 prescribing guidelines from manufacturers and medical societies

2. Understand your state’s rules

• Check your state’s scope-of-practice laws (if you’re an NP, do you need a collaborating physician?)
• Review any state-specific obesity treatment protocols (like Florida’s quarterly follow-up requirement)
• Confirm telehealth prescribing is allowed for controlled substances in your state (if you plan to prescribe phentermine)
• Register with your state’s Prescription Drug Monitoring Program

3. Build your clinical workflow

• Intake process: Collect weight, BMI, comorbidities, prior weight-loss attempts
• Initial evaluation: Comprehensive history (including psych history per NJ rules), review of systems, discussion of dietary/exercise habits
• Labs: Baseline metabolic panel, lipids, HbA1c, TSH (rule out secondary causes)
• Informed consent: Document risks, benefits, alternatives
• Follow-up schedule: Match state requirements (monthly for first few months, then quarterly or as needed)
• Insurance: Submit prior authorizations with all required documentation

4. Choose your practice model

• Hybrid approach (most common): Add weight management for existing psychiatric patients with weight concerns
• Dedicated weight management within your practice: Screen for psychiatric comorbidities, offer integrated care
• Join a telehealth platform: Let the platform handle patient acquisition, credentialing, billing — you focus on clinical care

5. Document everything

• Why weight-loss medication is indicated (BMI, comorbidities, failed lifestyle interventions)
• Your clinical reasoning (especially if you’re a PMHNP practicing outside traditional psych scope)
• Informed consent discussions
• PDMP checks (for controlled substances)
• Follow-up plans and patient progress

Should You Do This?

Adding weight-loss medication management makes sense if:

• You’re already treating patients with medication-induced weight gain or metabolic issues
• You’re interested in integrated psychiatric-metabolic care and willing to get additional training
• You practice in a state with reasonable regulations (avoid Florida if you want to prescribe phentermine via telehealth; focus on GLP-1s instead)
• You want a high-demand service line that’s increasingly reimbursed by insurance

It probably doesn’t make sense if:

• You have zero interest in metabolic issues and prefer to stay purely in psychiatric territory (totally valid)
• Your state makes it operationally difficult (e.g., you’re a solo NP in Texas and can’t find a collaborating physician)
• You’re not willing to invest in obesity medicine education

The opportunity is real. Obesity rates are rising. GLP-1s are proven effective. Insurance is finally covering treatment. Medicare coverage starting in 2026 will flood the market with eligible patients. Psychiatrists and PMHNPs who position themselves now as experts in integrated mental health and metabolic care will have a competitive advantage.

But do it right. Get trained. Follow state laws. Document thoroughly. Don’t shortcut the standard of care just because telehealth makes it easy to see patients quickly.

And if you want to skip the headache of building a weight-loss practice from scratch — the marketing, the credentialing, the billing — join a platform that brings qualified patients to you. You’ll get paid per appointment, avoid the upfront marketing gamble, and focus on what you do best: caring for patients.

Frequently Asked Questions

Can a psychiatrist legally prescribe GLP-1 weight-loss medications?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all states for FDA-approved medications, including GLP-1 agonists like Wegovy (semaglutide) and Saxenda (liraglutide). However, you should ensure you’re practicing within your competency — many psychiatrists pursue additional training in obesity medicine through CME courses or ABOM board certification to strengthen their expertise.

Do I need special certification to prescribe weight-loss drugs?

No special license is required beyond your medical/nursing license and DEA registration. However, competency matters. Some states (like Florida) require physicians to be ‘qualified by training and experience’ to prescribe obesity medications. Pursuing obesity medicine training or certification demonstrates competency and reduces regulatory risk.

Can PMHNPs prescribe weight-loss medications independently?

It depends on your state. About 26 states grant nurse practitioners Full Practice Authority, allowing independent prescribing after meeting experience requirements (e.g., New York after 3,600 hours, Illinois after 4,000 hours + 250 CE hours). In restricted states like Texas, Florida, and Pennsylvania, PMHNPs must have a collaborative agreement or protocol with a physician to prescribe. Even in independent states, some insurers may require physician involvement for high-cost GLP-1 prior authorizations.

Can I prescribe phentermine (controlled appetite suppressant) via telehealth?

It depends on your state. Federal law (DEA waivers through Dec 31, 2025) allows prescribing controlled substances via telehealth without an initial in-person visit. However, Florida prohibits telehealth prescribing of controlled substances for weight loss (only allowed for psychiatric treatment, addiction, or inpatient care). Alabama, South Carolina, and Idaho also require in-person exams. Texas, California, New York, Pennsylvania, and Illinois generally permit it if federal rules and standard of care are met. Always check your state’s specific telehealth laws.

Are GLP-1 medications safe for patients with psychiatric conditions?

Yes, current evidence is reassuring. A 2025 meta-analysis found no increase in depression or suicidality with GLP-1 medications versus placebo. The FDA and European regulators found no causal link to psychiatric adverse events. In fact, some studies show patients on GLP-1s report slightly lower depressive symptoms. Standard psychiatric monitoring is still recommended, especially in patients with active suicidal ideation or severe eating disorders.

What are the typical follow-up requirements for weight-loss medication management?

Requirements vary by state:

• Florida: At least every 3 months
• Virginia: Within 30 days of starting, then monthly initially
• New Jersey, California, New York, Texas, Pennsylvania, Illinois: No specific state-mandated frequency, but standard of care typically means monthly visits initially to monitor side effects and titrate dosing, then quarterly once stable

Best practice: Schedule regular follow-ups to assess weight loss progress, side effects, vital signs, and labs.

Will insurance cover weight-loss medications?

Increasingly, yes. Most major commercial insurers now cover FDA-approved obesity medications (Wegovy, Saxenda, Zepbound) with prior authorization. Requirements typically include BMI ≥30 (or ≥27 with comorbidity) and documentation of lifestyle interventions. Medicare announced in late 2025 it will begin covering anti-obesity medications — a game-changer for providers serving seniors. Medicaid coverage varies by state but is expanding.

How much can I earn from weight-loss medication management?

Reimbursement depends on your credential and payer:

• Psychiatrists: Paid at 100% of physician fee schedule. Initial evaluations (90792): ~$200. Follow-up med checks (99213/99214): ~$75-120.
• PMHNPs: Typically paid at 85% of physician rates by Medicare, 85-100% by commercial payers (Illinois Medicaid pays APRNs at 100% physician rates)
• Many providers combine weight management with existing psychiatric visits, adding value without necessarily adding appointment time

What’s the patient acquisition cost if I market my own weight-loss practice?

Realistic all-in cost: $200-500+ per booked patient when you factor in:

• SEO: $2,000-5,000/month for 6-12 months before results
• Google Ads: $15-40+ per click, realistic cost per booking $200-400+
• Directory listings: Monthly fees + per-booking charges
• Staff time, failed campaigns, no-show rates

For most providers, especially those starting out, the platform model (pay only when a patient books) eliminates upfront marketing risk and provides guaranteed ROI.

Is prescribing weight-loss meds outside a psychiatric NP’s scope of practice?

Scope is about competency, not specialty title. If you:

• Obtain additional training in obesity medicine
• Treat patients where weight issues intersect with mental health (med-induced weight gain, binge eating, metabolic effects of psychiatric meds)
• Work within required collaborative models
• Document your clinical rationale

…then it’s defensible. Many PMHNPs successfully integrate weight management as part of comprehensive patient care. Avoid advertising as a standalone weight-loss clinic without appropriate credentials, which could invite regulatory scrutiny.

What states have the most restrictive rules for PMHNPs prescribing weight-loss meds?

Texas and Florida are most restrictive:

• Texas: All NPs require Prescriptive Authority Agreements with physicians (monthly meetings, chart reviews, explicit formulary delegation)
• Florida: APRNs need physician protocols. Even ‘Autonomous APRNs’ (limited to primary care NPs, excluding psychiatric NPs) cannot independently prescribe controlled substances. Florida also bans telehealth controlled substance prescribing for weight loss.

Most permissive: California (phasing in NP independence by 2026), New York (independence after 3,600 hours), Illinois (Full Practice Authority after 4,000 hours).

Top 5 Citations

1. MedicalDirector Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (2025). Comprehensive analysis of NP scope-of-practice requirements and physician collaboration costs across states. www.medicaldirectorco.com

2. Florida Administrative Code R. 64B15-14.004 – Standards for Prescription of Obesity Drugs (Effective Aug 8, 2022). Official state regulation detailing BMI requirements, informed consent, follow-up protocols, and prescribing standards for weight-loss medications in Florida. www.law.cornell.edu

3. The Nurse Practitioner Journal – Susanne J. Phillips, ’36th Annual APRN Legislative Update: Improving Access and Removing Barriers’ (January 2024). Authoritative peer-reviewed summary of state-by-state NP scope-of-practice laws and legislative changes. journals.lww.com

4. RxAgent.co – ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ (Dec 16, 2025). Analysis of state-level telehealth prescribing restrictions for controlled substances despite federal DEA waivers, with specific focus on Florida, Alabama, and other restricted states. rxagent.co

5. DrLewis.com (Elliott Lewis, MD) – ‘Should Psychiatrists Prescribe GLP-1s? An Evidence-Based Perspective’ (Jan 4, 2026). Board-certified psychiatrist and obesity medicine specialist’s analysis of scope-of-practice considerations, safety data, and clinical rationale for psychiatric providers prescribing GLP-1 medications. drlewis.com

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting